New trial
Phase IIIb Study: Ribociclib CDK4/CDK6 Inhibitor in HR+ HER2- Early Breast Cancer Adjuvant Setting
- Trial ID
- NCT05827081 on ClinicalTrials.gov
- Cancer type
- Breast Cancer
- Stage of research
- Registrational
- Location
- 34 Locations
- Published in
- New in Oncology - July 11, 2025
The trial evaluates safety and efficacy of ribociclib, a CDK4/CDK6 inhibitor, combined with standard adjuvant endocrine therapy in HR+ HER2- early-stage breast cancer patients, including a subgroup with Stage IIA disease. This open-label, single-arm study by Novartis tests a 36-month regimen to assess invasive breast cancer-free survival; eligible patients have Stage I-III HR+ HER2- breast cancer receiving adjuvant endocrine therapy.
More in breast cancer
-
Trial result · Oct 22, 2026 · NCT02364557
NRG-BR002: Metastasis-directed ablation (SBRT/surgery) fails to extend PFS in oligometastatic breast cancer on 1L systemic therapy -
Trial result · Oct 22, 2026 · NCT05963984
Samuraciclib + fulvestrant shows higher clinical benefit and numerically longer PFS after CDK4/6 inhibition in randomized Phase 2 breast cancer trial -
Trial result · Oct 15, 2026 · NCT05306340
Giredestrant (oral SERD) + everolimus improves PFS after CDK4/6 inhibition, with the strongest benefit in ESR1-mutated breast cancer -
Trial result · Oct 15, 2026 · NCT02264678
Ceralasertib (ATR inhibitor) + Olaparib (PARP inhibitor) hits 37.8% ORR in PARPi‑naïve BRCA‑mut HER2‑neg breast cancer -
New trial · Oct 15, 2026 · NCT07844759
Pilot study tests single-fraction stereotactic radiation plus endocrine therapy without lumpectomy in early breast cancer